{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:20:31Z","timestamp":1793017231921,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.msard.2023.104556","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T02:23:35Z","timestamp":1676082215000},"page":"104556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Predictors of hospitalization due to infection in rituximab-treated MS patients"],"prefix":"10.1016","volume":"71","author":[{"given":"Jakob Rishovd","family":"Karlowicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Klakegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Harald","family":"Aarseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"B\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell-Morten","family":"Myhr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde Marie","family":"Torgauten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ivind","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-7686","authenticated-orcid":false,"given":"Stig","family":"Wergeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.msard.2023.104556_bib0001","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.msard.2023.104556_bib0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","article-title":"Rituximab for the treatment of multiple sclerosis: a review","volume":"269","author":"Chisari","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2023.104556_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102987","article-title":"Natalizumab differentially affects plasmablasts and B cells in multiple sclerosis","volume":"52","author":"Cuculiza Henriksen","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104556_bib0004","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMA Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104556_bib0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.msard.2013.10.003","article-title":"Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica","volume":"3","author":"Graves","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2023.104556_bib0006","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.msard.2023.104556_bib0007","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.msard.2023.104556_bib0008","doi-asserted-by":"crossref","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","article-title":"Safety of Ocrelizumab in patients with relapsing and primary progressive multiple sclerosis","volume":"97","author":"Hauser","year":"2021","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.msard.2023.104556_bib0009","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2023.104556_bib0010","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2023.104556_bib0011","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol."},{"issue":"11","key":"10.1016\/j.msard.2023.104556_bib0012","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"Predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthrit. Rheumatol."},{"issue":"3","key":"10.1016\/j.msard.2023.104556_bib0013","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2023.104556_bib0014","first-page":"765","article-title":"Drug-induced neutropenia: a focus on rituximab-induced late-onset neutropenia","volume":"41","author":"Moore","year":"2016","journal-title":"P t"},{"key":"10.1016\/j.msard.2023.104556_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103082","article-title":"Multiple sclerosis and immune system biomarkers: Novel comparison in glatiramer acetate and interferon beta-1a-treated patient groups","volume":"53","author":"Pavelek","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2023.104556_bib0016","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001115","article-title":"Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with rituximab","volume":"9","author":"Perriguey","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2023.104556_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102019","article-title":"Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases","volume":"41","author":"Rigal","year":"2020","journal-title":"Mult. Scler Relat. Disord."},{"issue":"20","key":"10.1016\/j.msard.2023.104556_bib0018","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2023.104556_bib0019","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/rheumatology\/kez349","article-title":"The association between lymphopenia and serious infection risk in rheumatoid arthritis","volume":"59","author":"Subesinghe","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.msard.2023.104556_bib0020","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1586\/ehm.11.62","article-title":"Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms","volume":"4","author":"Tesfa","year":"2011","journal-title":"Expert Rev. Hematol."},{"issue":"9","key":"10.1016\/j.msard.2023.104556_bib0021","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.msard.2023.104556_bib0022","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Annal. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2023.104556_bib0023","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419878340","article-title":"Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course","volume":"12","author":"Zoehner","year":"2019","journal-title":"Ther. Adv. Neurol. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034823000603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:04:22Z","timestamp":1761901462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034823000603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":23,"alternative-id":["S2211034823000603"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2023.104556","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of hospitalization due to infection in rituximab-treated MS patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2023.104556","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104556"}}